Welcome to our dedicated page for Biomx SEC filings (Ticker: PHGE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The BiomX Inc. (PHGE) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures, including Form 8-K current reports and other key documents filed with the U.S. Securities and Exchange Commission. These filings offer detailed information on BiomX’s clinical-stage phage therapy programs, corporate actions and financing arrangements, and they complement the company’s press releases for investors researching PHGE stock.
BiomX’s recent Form 8-K filings describe several material events. These include the initiation and terms of a private placement of Series Y Convertible Preferred Stock and related warrants, with details on dividend rights, conversion mechanics, exercise prices, registration rights and stockholder approval requirements. Other 8-Ks outline the authorization and implementation of a one-for-nineteen reverse stock split of the common stock listed on NYSE American under the symbol PHGE, along with proportional adjustments to equity awards, warrants and convertible preferred stock.
Filings also document significant developments in BiomX’s clinical and operational landscape. The company has reported an FDA clinical hold on the U.S. portion of its BX004 Phase 2b study, subsequent FDA follow-up questions on a third-party nebulizer device, and the eventual discontinuation of the BX004 Phase 2b trial after internal review and Data Monitoring Committee recommendations. Additional 8-Ks describe cost-cutting measures, workforce reductions, and the decision by the board of BiomX Ltd., an Israeli subsidiary, to approve and authorize the filing of an application to commence insolvency proceedings. Lease termination terms for Adaptive Phage Therapeutics, LLC, a wholly owned subsidiary, are also set out in detail.
Through this page, users can review how BiomX reports on its BX011 and BX211 phage programs for diabetic foot disease, its capital structure changes, and board and governance matters. Stock Titan enhances these filings with AI-powered summaries that highlight key terms, clinical implications and capital market impacts, helping readers quickly understand complex items such as preferred stock designations, warrant adjustments, clinical trial disclosures and strategic alternatives discussed in BiomX’s SEC reports.
BiomX Inc. director and 10% owner Reuven Yeganeh filed an initial Form 3 reporting indirect holdings through Pyu Pyu Capital, LLC as of January 13, 2026. The filing shows Series Y Convertible Preferred Stock initially convertible into 1,650,000 shares of common stock at $2.00 per share, with customary anti-dilution adjustments and potential further adjustment upon requisite stockholder approval. It also reports Common Stock Purchase Warrants for 3,300,000 shares of common stock at an exercise price of $2.00, exercisable from January 2, 2026 and expiring on January 2, 2031. According to the filing, Pyu Pyu Capital, LLC holds these securities, and Yeganeh is its sole member with sole voting and dispositive power.
BiomX Inc. reports that it has closed a previously announced private placement, created a new preferred share class, and adjusted its board structure. On January 13, 2026, the company completed a private placement tied to a Securities Purchase Agreement dated December 26, 2025 and, in connection with the closing, issued 3,300 shares of Series Y Convertible Preferred Stock along with warrants to purchase common stock. The company filed a Certificate of Designations in Delaware to establish the rights of this new Series Y preferred stock.
The board had previously expanded to nine members and appointed Reuven Yeganeh as a Class 1 director, effective at the private placement closing, with a term running until the 2027 annual meeting, subject to the Lead Buyer maintaining at least 9.99% beneficial ownership of common stock on an as-converted basis. BiomX determined that Mr. Yeganeh qualifies as an independent director under NYSE American rules and entered into a standard-form indemnification agreement with him, consistent with those for its other directors.
BiomX Inc. reported that its wholly owned subsidiary, Adaptive Phage Therapeutics, LLC (APT), has terminated its lease for premises in Gaithersburg, Maryland, effective December 31, 2025. The termination was completed through a Seventh Amendment to the lease agreement with the landlord, ARE-708 Quince Orchard, LLC.
Under this amendment, APT agreed to make a one-time payment of $800,000 to the landlord, and the landlord confirmed its draw on an existing letter of credit of $153,557.68. After these conditions and other requirements in the amendment are satisfied, the landlord agreed to release APT and BiomX from any further obligations and liabilities under the lease, except for certain limited obligations that continue.
BiomX Inc. entered into a private placement with an investor, agreeing to sell 3,300 shares of new Series Y Convertible Preferred Stock with an aggregate stated value of $3.3 million and related warrants for expected gross proceeds of $3.0 million before fees. The Series Y Preferred Stock carries a 15% annual dividend, a one-year maturity, and is initially convertible into common stock at $2.00 per share, with the conversion price subject to potential reduction after stockholder approval based on the market price.
The investor will also receive warrants to purchase 3,300,000 common shares at an initial exercise price of $2.00, exercisable immediately for five years, with a similar potential exercise-price reduction after stockholder approval. Beneficial ownership is capped at up to 19.99% before such approval, and BiomX will seek stockholder approval within 60 days and file a resale registration statement within 30 days of closing. The investor may designate up to two directors depending on its ownership level, and placement agent H.C. Wainwright & Co. will receive cash fees and 99,000 warrants at an exercise price of $2.50.
BiomX Inc. reported that its Israeli subsidiary, BiomX Ltd., will seek insolvency proceedings under the Israeli Insolvency and Financial Regulation law 5778-2018. This follows the earlier discontinuation of a Phase 2b clinical study after the company concluded that the timelines and resources required for an alternative dosing strategy exceeded its available resources.
In light of these limited financial resources, the BiomX Ltd. board authorized filing the insolvency application on December 11, 2025. BiomX Inc. states that it is evaluating strategic options and continues to own its BX011 program for diabetic foot infections, which is being conducted by its other subsidiary, Adaptive Phage Therapeutics, Inc.
BiomX Inc. reported that it is discontinuing its ongoing Phase 2b clinical trial of BX004 in cystic fibrosis patients with chronic Pseudomonas aeruginosa infections. Management concluded that the timelines and resources needed to pursue an alternative dosing strategy recommended by the independent Data Monitoring Committee were beyond the company’s available resources.
BiomX is implementing cost-cutting measures, including a significant reduction of its workforce, and plans to concentrate its efforts on advancing its bacteriophage-based therapeutics, particularly BX011 for diabetic foot infections, if sufficient financial and other resources are available. The company is also reviewing other strategic alternatives while noting that these plans involve forward-looking statements subject to substantial risks and uncertainties.
BiomX Inc. (PHGE) reported an update on its Phase 2b study of BX004 for treating cystic fibrosis. The U.S. FDA is continuing its clinical hold while it evaluates a third-party nebulizer device used to deliver BX004, and BiomX is working with the device manufacturer to answer follow-up FDA information requests in order to lift the hold. The company believes the remaining items are readily addressable and expects U.S. enrollment to resume once this process is complete and subject to available financing. An independent Data Monitoring Committee completed a safety review of the study, including participants who experienced adverse events, and recommended the trial continue with an adjusted dosing regimen. BiomX is updating the protocol accordingly and, depending on financial resources and other factors, now expects topline results in the second quarter of 2026.
BiomX Inc. announced that its board approved a one-for-nineteen (1:19) reverse stock split of its common stock. The split is scheduled to take effect at 12:01 a.m. Eastern Time on November 25, 2025, with BiomX shares expected to begin trading on the NYSE American on a split-adjusted basis that same day. Every nineteen existing shares will be combined into one new share, without changing the total number of shares the company is authorized to issue or the par value or rights of the common stock. Stockholders will not receive fractional shares; instead, positions will be rounded up to the nearest whole share, and outstanding equity awards, warrants, convertible preferred stock and plan share limits will be adjusted proportionally.
BiomX (PHGE) reported Q3 2025 results marked by ongoing R&D progress alongside tight liquidity. The company posted a net loss of $9.166M and an operating loss of $8.536M. R&D expenses, net, were $6.122M (down 16% year over year), and G&A expenses were $2.414M (down 25%).
Cash resources remain limited. Cash, cash equivalents and restricted cash were $8.069M at September 30, 2025. For the nine months, cash used in operating activities totaled $22.004M, partly offset by $11.938M of financing inflows, including February 2025 capital actions and modest ATM sales. Management states current funds are sufficient into Q1 2026 and notes substantial doubt about the ability to continue as a going concern.
On the pipeline, the Phase 2b CF study of BX004 continues in Europe, while the FDA placed a clinical hold in August 2025 related to the third‑party nebulizer device; no issues were raised regarding BX004 itself. BiomX believes it has addressed FDA device queries and expects topline results in Q1 2026. The company also reported positive Phase 2 results in DFO (BX211) and plans to advance BX011 in DFI subject to resources. Shares outstanding were 29,006,165 as of November 11, 2025.
BiomX Inc. (PHGE) filed an 8-K stating it furnished a press release announcing financial results for the third quarter ended September 30, 2025. The release was provided under Item 2.02 and attached as Exhibit 99.1. This is a standard disclosure to make the company’s quarterly results announcement part of the public record.